A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Vorinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 20 Dec 2011 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 18 Sep 2008 Additional trial identifier MK0683-029 as reported by ClinicalTrials.gov.
- 18 Sep 2008 Planned patient number (21) added as reported by ClinicalTrials.gov.